ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2026
Is EQ-5D-5L sensitive enough to detect treatment-related changes in health status of prostate cancer patients? A nationwide Norwegian longitudinal study from the prostate cancer registry.
Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo examine the generic European Quality of Life 5-Dimensions questionnaire (EQ-5D-5L) responsiveness to change in health status of patients with invasive prostate cancer (PCa) from pre- to post-treatment and compare these results with the responsiveness of disease-specific instruments assumed to be particularly sensitive to change in a large sample of PCa patients.
methodsIn this nationwide registry study (2017–2019), PCa patients in Norway (n = 620) and a matched reference group from the general population without previous cancer history (n = 1776) were invited. All participants completed the EQ-5D-5L, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) and the Expanded Prostate Cancer Index Composite short form (EPIC-26) pre- and post-treatment. Paired t-tests were performed with latent change scores in a structural equation model framework.
resultsEQ-5D-5L showed minor changes from pre- to post-treatment for four dimensions and sum score (Cohen’s d ≤ 0.20). EORTC-QLQ-C30 revealed a moderate decline in social function (-9.85, p < 0.001, Cohen’s d -0.52). EPIC-26 showed a large decline in sexual function (-38.1, p < 0.001, Cohen’s d -1.42), and urine incontinency (-24.3, p < 0.001, Cohen’s d -1.86). Correlations between change in EQ-5D-5L and change in domains found to be important for participants with PCa (sexual function, urine incontinence and social function) revealed small to medium correlations for the PCa group.
conclusionsThe low responsiveness indicates that the EQ-5D-5L is not sensitive enough in detecting health status changes due to significant problem areas in PCa patients. Adding disease-specific measures is pivotal to measuring these changes in health status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.